Top

International Journal of Colorectal Disease

Published in:

01-03-2004 | Original Article

Analysis of the therapeutic efficacy of different doses of budesonide in patients with active Crohn's ileocolitis depending on disease activity and localization

Authors: H. Herfarth, V. Gross, T. Andus, I. Caesar, H. Vogelsang, G. Adler, H. Malchow, A. Petri, M. Gierend, J. Schölmerich, The German/Austrian Budesonide Study Group

Published in: International Journal of Colorectal Disease | Issue 2/2004

Abstract

Background and aims

The nonsystemic steroid budesonide has been used to treat active ileocecal and ileocolonic Crohn's disease (CD). This study investigated the optimal budesonide dose using a pH-dependent release formulation. The goal of treatment was the remission of CD (CDAI <150) within 6 weeks of treatment.

Patients and methods

The study was of randomized, double-blind, dose-finding design. Patients with active CD ileocolitis without steroid pretreatment were treated with 3×2 mg (n=39), 3×3 mg (n=33), or 3×6 mg (n=32) oral pH-modified released budesonide daily.

Results

The remission rates after 6 weeks were 36% with 3×2 mg, 55% with 3×3 mg, and 66% with 3×6 mg. Significantly more patients were in remission while treated with 3× 6mg than with 3×2 mg budesonide/day. Subgroup analyses revealed that patients with high disease activity (CDAI ≥ 300) or ileocolonic disease with disease manifestation distal to the transverse colon responded better to the highest budesonide dose.

Conclusion

Oral pH-modified released budesonide shows a dose-dependent effectiveness in patients with active ileocolonic CD. In the majority of patients 9 mg budesonide per day is sufficient. However, in patients with highly active disease or ileal disease with distal colonic manifestation higher doses of budesonide could increase the therapeutic response

Summers RW, Switz DM, Sessions JT Jr, Becktel JM, Best WR, Kern F Jr, Singleton JW (1979) National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 77:847–869

Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, Jesdinsky H (1984) European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 86:249–266PubMed

Campieri M (2002) New steroids and new salicylates in inflammatory bowel disease: a critical appraisal. Gut 50 [Suppl III]:43–46

Wright JP, Jarnum S, Schaffalitzky de Muckadell OB, Keech ML, Lennard-Jones JE (1993) Oral fluticasone propionate compared with prednisolone in treatment of active Crohn's disease: a randomized double-blind multicenter study. Eur J Gastroenterol Hepatol 5:499–503

Spencer CM, McTavish D (1995) Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease. Drugs 50:854–872PubMed

Lofberg R, Danielsson A, Salde L (1993) Oral budesonide in active Crohn's disease. Aliment Pharmacol Ther 7:611–616PubMed

Roth M, Gross V, Scholmerich J, Ueberschaer B, Ewe K (1993) Treatment of active Crohn's disease with an oral slow-release budesonide formulation. Am J Gastroenterol 88:968–969

Caesar I, Gross V, Roth M, Andus T, Schmidt C, Raedsch R, Weber A, Gierend M, Ewe K, Scholmerich J (1995) Treatment of active Crohn's ileocolitis with oral pH-modified budesonide. Germany Budesonide Study Group. Z Gastroenterol 33:247–250

Rutgeerts P, Lofberg R, Malchow H, Lamers C, Olaison G, Jewell D, Danielsson A, Goebell H, Thomsen OO, Lorenz-Meyer H et al (1994) A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 331:842–845

10.

Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, Nilsson LG, Persson T (1994) Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 331:836–841

11.

Campieri M, Ferguson A, Doe W, Persson T, Nilsson LG (1997) Oral budesonide is as effective as oral prednisolone in active Crohn's disease. Gut 41:209–214

12.

Gross V, Andus T, Caesar I, Bischoff SC, Lochs H, Tromm A, Schulz HJ, Bar U, Weber A, Gierend M, Ewe K, Scholmerich J (1996) Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. Eur J Gastroenterol Hepatol 8:905–909

13.

Thomsen OO, Cortot A, Jewell D, Wright JP, Winter T, Veloso FT, Vatn M, Persson T, Pettersson E (1998) A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. N Engl J Med 339:370–374

14.

Bar-Meir S, Chowers Y, Lavy A, Abramovitch D, Sternberg A, Leichtmann G, Reshef R, Odes S, Moshkovitz M, Bruck R, Eliakim R, Maoz E, Mittmann U (1998) Budesonide versus prednisone in the treatment of active Crohn's disease. Gastroenterology 115:835–840

15.

Papi C, Luchetti R, Gili L, Montanti S, Koch M, Capurso L (2000) Budesonide in the treatment of Crohn's disease: a meta-analysis. Aliment Pharmacol Ther 14:1419–1428

16.

Rutgeerts PJ (2001) Review article: the limitations of corticosteroid therapy in Crohn's disease. Aliment Pharmacol Ther 15:1515–1525

17.

Naber AH, Olaison G, Smedh K, Jansen JB, Sjoddahl R (1996) Pharmacokinetics of budesonide controlled ileal release capsules in active Crohn's disease. Gastroenterology 110:A977

18.

Nilsson M, Edsbacker S, Larrson P, Wiren JE (1995) Dose-proportional kinetics of budesonide controlled ileal release capsules. Gastroenterology 108:A885

19.

Mollmann HW, Barth J, Hochhaus G, Mollmann AC, Derendorf H, Tromm A (1996) Principles of topical versus systemic corticoid treatment in inflammatory bowel disease. In: Mollmann HW, May B (eds) Glucocortoid therapy in chronic inflammatory bowel disease. Kluwer, Dordrecht, pp 42–60

20.

Mollmann HW, Hochhaus G, Tromm A, Moellmann A, Derendorf H, Barth J, Froehlich P, Ecker KW, Lindemann A (1996) Pharmacokinetics and evaluation of systemic side effects of budesonide after oral administration of modified release capsules in healthy volunteers, ileostoma patients and patients with Crohn's disease (abstract). Gastroenterology 110:A972

21.

Green JR, Lobo AJ, Giaffer M, Travis S, Watkins HC (2001) Maintenance of Crohn's disease over 12 months: fixed versus flexible dosing regimen using budesonide controlled ileal release capsules. Aliment Pharmacol Ther 15:1331–1341

22.

Caesar I, Gross V, Roth M, Andus T, Schmidt C, Raedsch R, Weber A, Gierend M, Ewe K, Scholmerich J (1997) Treatment of active and postactive ileal and colonic Crohn's disease with oral pH-modified-release budesonide. German Budesonide Study Group. Hepatogastroenterology 44:445–451

23.

Lofberg R, Danielsson A, Suhr O, Nilsson A, Schioler R, Nyberg A, Hultcrantz R, Kollberg B, Gillberg R, Willen R, Persson T, Salde L (1996) Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology 110:1713–1718

24.

Feagan BG (1996) Oral budesonide therapy for ulcerative colitis: a topical tale. Gastroenterology 110:2000–2002

25.

Tremaine WJ, Hanauer SB, Katz S, Winston BD, Levine JG, Persson T, Persson A (2002) Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States. Am J Gastroenterol 97:1748–1754

Title: Analysis of the therapeutic efficacy of different doses of budesonide in patients with active Crohn's ileocolitis depending on disease activity and localization
Authors: H. Herfarth
V. Gross
T. Andus
I. Caesar
H. Vogelsang
G. Adler
H. Malchow
A. Petri
M. Gierend
J. Schölmerich
The German/Austrian Budesonide Study Group
Publication date: 01-03-2004
Publisher: Springer-Verlag
Published in: International Journal of Colorectal Disease / Issue 2/2004
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-003-0529-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Analysis of the therapeutic efficacy of different doses of budesonide in patients with active Crohn's ileocolitis depending on disease activity and localization

Abstract

Background and aims

Patients and methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background and aims

Patients and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2004

Total cystectomies in the surgical treatment of rectal cancer with prior chemoradiation: analysis of postoperative morbidity and survival

Gangrenous sigmoid volvulus: a clinical study of 76 patients

Identification of occult tumor cells in node negative lymph nodes of colorectal cancer patients by cytokeratin 20 gene and protein expression

Anastomotic leakage following low anterior resection: results of a standardized diagnostic and therapeutic approach

Hypomethylation of L1 retrotransposons in colorectal cancer and adjacent normal tissue

Long-term effect of 5-fluorouracil enhanced by intermittent administration of polysaccharide K after curative resection of colon cancer